Skip to main content
64°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Rallybio Corporation
< Previous
1
2
Next >
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis
April 06, 2023
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)
April 03, 2023
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results
March 06, 2023
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
March 06, 2023
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio to Present at Upcoming Investor Conferences in March
March 01, 2023
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy
February 27, 2023
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer
January 31, 2023
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023
January 05, 2023
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT
December 15, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
December 01, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
ABCL
RLYB
Rallybio to Present at the JMP Securities Hematology and Oncology Summit
November 29, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio to Present at Upcoming Investor Conferences in November
November 11, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Announces Proposed Public Offering
November 10, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
November 07, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
September 28, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio to Present at the 2022 Wells Fargo Healthcare Conference
August 31, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Reports Second Quarter 2022 Financial Results
August 08, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors
August 02, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer
June 02, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio to Present at Upcoming Investor Conferences in June
June 01, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Reports First Quarter 2022 Financial Results
May 10, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi
May 10, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors
April 04, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results
March 15, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio to Present at the Cowen 42nd Annual Health Care Conference
February 28, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Ami Bavishi Joins Rallybio to Lead Investor Relations and Corporate Communications
January 18, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Highlights Portfolio Advances and Outlines Expected Upcoming Milestones for 2022
January 06, 2022
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
December 01, 2021
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
Rallybio Corporation to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 24, 2021
From
Rallybio Corporation
Via
Business Wire
Tickers
RLYB
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.